Ligand Pharmaceuticals Inc (LGND)

109.48
0.58 0.53
NASDAQ : Health Care
Prev Close 108.90
Open 109.01
Day Low/High 107.51 / 109.50
52 Wk Low/High 71.63 / 138.94
Volume 139.23K
Avg Volume 270.20K
Exchange NASDAQ
Shares Outstanding 20.92M
Market Cap 2.20B
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Ligand To Participate In Upcoming Investor Conference

Ligand To Participate In Upcoming Investor Conference

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that company executives are scheduled to participate in the following upcoming investor conference: 29 th Annual ROTH Conference in Laguna...

Ligand Provides Highlights From Today's Analyst Day Event

Ligand Provides Highlights From Today's Analyst Day Event

At an Analyst Day event held today in New York City, Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) reviewed the recent progress of its business, its revenue growth opportunities and its portfolio of partnered assets...

Ligand Expands License With Sermonix To Include Worldwide Rights For Oral Lasofoxifene

Ligand Expands License With Sermonix To Include Worldwide Rights For Oral Lasofoxifene

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that it has expanded its license with Sermonix Pharmaceuticals to include worldwide rights to develop and commercialize oral lasofoxifene.

6 Stocks with Unusual Volume Activity

6 Stocks with Unusual Volume Activity

When stocks move with unusual volume, it can signal insider buying and selling.

6 Stocks on the Move With Unusual Volume

6 Stocks on the Move With Unusual Volume

Here's a technical look at how to trade a number of stocks rising with unusual volume flow.

Enrollment Completed In Ligand's Phase 2 Trial Of LGD-6972 In Type 2 Diabetes

Enrollment Completed In Ligand's Phase 2 Trial Of LGD-6972 In Type 2 Diabetes

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announces the completion of enrollment in the Company's Phase 2 clinical trial with its novel, small-molecule glucagon receptor antagonist LGD-6972 for the treatment of...

Ligand Reports Fourth Quarter And Full Year 2016 Financial Results

Ligand Reports Fourth Quarter And Full Year 2016 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2016, and provided an operating forecast and program updates.

Dr. Christel Iffland Joins Ligand As Vice President, Antibody Technologies, Expands Team Focused On OmniAb Drug Discovery Platform

Dr. Christel Iffland Joins Ligand As Vice President, Antibody Technologies, Expands Team Focused On OmniAb Drug Discovery Platform

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the appointment of Christel Iffland, Ph.

Reminder: Ligand To Host Analyst Day On February 28th In New York City

Reminder: Ligand To Host Analyst Day On February 28th In New York City

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host an Analyst Day on Tuesday, February 28, 2017 from 10:00 a.

Ligand To Host Analyst Day On February 28th In New York City

Ligand To Host Analyst Day On February 28th In New York City

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host an Analyst Day on Tuesday, February 28, 2017 from 10:00 a.

Ligand To Report Fourth Quarter And Full Year 2016 Results On February 23rd

Ligand To Report Fourth Quarter And Full Year 2016 Results On February 23rd

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report fourth quarter and full year 2016 financial results on February 23, 2017.

Lemelson Capital Management Announces 2016 Performance Results For The Amvona Fund, LP

Lemelson Capital Management Announces 2016 Performance Results For The Amvona Fund, LP

Firm's flagship fund returns 84.97 percent net of all fees and expenses in 2016

UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders Of Ligand Pharmaceuticals Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 17, 2017

UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders Of Ligand Pharmaceuticals Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 17, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Ligand Pharmaceuticals Inc.

LGND SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Ligand Pharmaceuticals Inc. And A Lead Plaintiff Deadline Of January 17, 2017

LGND SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Ligand Pharmaceuticals Inc. And A Lead Plaintiff Deadline Of January 17, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors who purchased Ligand Pharmaceuticals Inc.

DEADLINE ALERT: Brower Piven Reminds Investors Of The January 17, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess Of $100,000 From Investment In Ligand Pharmaceuticals Incorporated To Contact The Firm

DEADLINE ALERT: Brower Piven Reminds Investors Of The January 17, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess Of $100,000 From Investment In Ligand Pharmaceuticals Incorporated To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of California on behalf...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Ligand Pharmaceuticals Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 17, 2017

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Ligand Pharmaceuticals Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 17, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Ligand Pharmaceuticals Inc.

Ligand Enters Commercial License And Supply Agreements For Captisol®-enabled Trametinib

Ligand Enters Commercial License And Supply Agreements For Captisol®-enabled Trametinib

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into global license and supply agreements with Novartis for the development and commercialization of a Captisol-enabled oral liquid formulation of...

Ligand Enters Into Worldwide OmniAb® Platform License Agreement With ONO PHARMACEUTICAL CO., LTD.

Ligand Enters Into Worldwide OmniAb® Platform License Agreement With ONO PHARMACEUTICAL CO., LTD.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with ONO PHARMACEUTICAL CO.

Lantern Foundation Founder Urges Senate Committee To Commence Investigation Into Ligand Pharmaceuticals

Lantern Foundation Founder Urges Senate Committee To Commence Investigation Into Ligand Pharmaceuticals

Abuse of Orphan Drug Act, Accounting and Ethical Violations Warrant Congressional and Regulatory Investigation, Organization's Founder Says

LGND SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Ligand Pharmaceuticals Inc. And A Lead Plaintiff Deadline Of January 17, 2017

LGND SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Ligand Pharmaceuticals Inc. And A Lead Plaintiff Deadline Of January 17, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors who purchased Ligand Pharmaceuticals Inc.

LGND NOTICE: Rosen Law Firm Reminds Ligand Pharmaceuticals Incorporated Investors Of Important Deadline In Class Action Filed By Firm - LGND

LGND NOTICE: Rosen Law Firm Reminds Ligand Pharmaceuticals Incorporated Investors Of Important Deadline In Class Action Filed By Firm - LGND

Rosen Law Firm, a global investor rights law firm, reminds purchasers of Ligand Pharmaceuticals Incorporated securities (NASDAQ:LGND) from November 9, 2015 through November 14, 2016, both dates inclusive (the "Class...

SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Ligand Pharmaceuticals Incorporated And Encourages Investors With Losses To Contact The Firm

SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Ligand Pharmaceuticals Incorporated And Encourages Investors With Losses To Contact The Firm

Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ligand Pharmaceuticals Incorporated ("Ligand" or the "Company") (Nasdaq: LGND).